| Literature DB >> 35856046 |
Ryoma Taniuchi1,2, Toshihide Harada3, Hiroaki Nagatani1, Takako Makino4, Chigusa Watanabe4, Shusaku Kanai3.
Abstract
Introduction: Although retropulsion is a serious complication of Parkinson's disease (PD), it is unknown whether ankle joint movement patterns can be targeted to treat retropulsion. The primary aim of this study was to investigate the effectiveness of therapeutic exercise focused on instructions regarding ankle joint movement on retropulsion in PD.Entities:
Keywords: Exercise therapy; Parkinson’s disease; Postural balance; Randomized controlled trial; Rehabilitation
Year: 2022 PMID: 35856046 PMCID: PMC9287626 DOI: 10.1016/j.prdoa.2022.100151
Source DB: PubMed Journal: Clin Park Relat Disord ISSN: 2590-1125
Fig. 1Flow diagram of the study participants.
Baseline demographic and clinical characteristics of the study groups.
| INSTR (n = 10) | Control (n = 10) | p-value | |
|---|---|---|---|
| Gender (Male/Female)b | 5/5 | 5/5 | > 0.99 |
| Age (years)a | 76.2 ± 6.4 | 73.5 ± 8.2 | 0.529 |
| Modified H-Yb | 0.809 | ||
| Stage 2.5, n (%) | 2 (20.0) | 1 (10.0) | |
| Stage 3, n (%) | 5 (50.0) | 6 (60.0) | |
| Stage 4, n (%) | 3 (30.0) | 3 (30.0) | |
| Disease duration (years)a | 7.3 ± 2.8 | 7.4 ± 3.6 | 0.739 |
| MMSEa | 26.6 ± 2.4 | 27.2 ± 2.3 | 0.631 |
| People who fell in the past year, n (%)b | 5 (50.0) | 6 (60.0) | 0.653 |
| Dominant hand (Right/Left)b | 10/0 | 7/3 | 0.060 |
| Occupational therapy intervention, n (%)b | 9 (90.0) | 9 (90.0) | > 0.99 |
| Medications | |||
| Daily levodopa equivalent dose (mg)a | 380.0 ± 141.8 | 430.0 ± 133.7 | 0.315 |
| Participants receiving dopamine agonists, n (%)b | 8 (80.0) | 7 (70.0) | 0.606 |
| Participants receiving MAO type B inhibitors, n (%)b | 2 (20.0) | 2 (20.0) | > 0.99 |
| Participants receiving COMT inhibitors, n (%)b | 3 (30.0) | 1 (10.0) | 0.264 |
| Participants receiving amantadine, n (%)b | 1 (10.0) | 0 (00.0) | 0.305 |
| Participants receiving droxidopa, n (%)b | 1 (10.0) | 1 (10.0) | > 0.99 |
| Participants receiving zonisamide, n (%)b | 4 (40.0) | 4 (40.0) | > 0.99 |
Data are expressed as mean ± SD unless stated otherwise.
Abbreviations: H-Y, Hoehn and Yahr; MMSE, Mini-Mental State Examination; MAO, monoamine oxidase; COMT, catechol-O-methyltransferase.
aMann-Whitney U test.
bChi-square test.
Results of the primary and secondary outcomes.
| T0 (baseline) | T1 (week 1) | T2 (week 2) | ANCOVA between group | ||
|---|---|---|---|---|---|
| ΔT0-T1 | ΔT0-T2 | ||||
| Mean ± SD | Mean ± SD | Mean ± SD | F/p-value‡ (pη2) | F/p-value‡ (pη2) | |
| MDS-UPDRS part III scores | |||||
| Total score† | |||||
| INSTR | 38.4 ± 11.4 | 28.8 ± 8.9** | 23.1 ± 10.3** | 5.4/0.033* (0.241) | 11.4/0.004** (0.401) |
| Control | 39.0 ± 13.6 | 32.4 ± 12.2** | 28.1 ± 11.2** | ||
| Tremor subscore† | |||||
| INSTR | 2.9 ± 2.6 | 1.7 ± 2.2* | 1.5 ± 1.5* | 0.1/0.808 (0.004) | 0.5/0.477 (0.030) |
| Control | 2.0 ± 2.0 | 1.0 ± 1.5 | 0.8 ± 1.2 | ||
| Rigidity subscore† | |||||
| INSTR | 8.9 ± 3.7 | 7.7 ± 3.4* | 6.9 ± 3.1* | 0.2/0.689 (0.010) | 0.2/0.634 (0.014) |
| Control | 8.2 ± 3.5 | 7.3 ± 3.1* | 6.7 ± 3.0* | ||
| Bradykinesia subscore† | |||||
| INSTR | 18.6 ± 5.0 | 14.5 ± 4.4** | 11.5 ± 5.8** | 2.1/0.170 (0.108) | 0.8/0.384 (0.045) |
| Control | 19.8 ± 8.6 | 16.8 ± 7.3* | 13.6 ± 7.1** | ||
| Axial subscore† | |||||
| INSTR | 8.0 ± 2.8 | 4.9 ± 2.6** | 3.2 ± 2.2** | 5.0/0.040* (0.226) | 16.9/< 0.001*** (0.498) |
| Control | 9.0 ± 2.5 | 7.3 ± 3.3* | 7.0 ± 3.1** | ||
| Pull test† | |||||
| INSTR | 2.7 ± 0.7 | 1.0 ± 1.2* | 0.1 ± 0.3** | 1.5/0.231 (0.083) | 12.3/0.003** (0.419) |
| Control | 2.4 ± 0.8 | 1.5 ± 1.4* | 1.4 ± 1.3* | ||
| TUG (s)† | |||||
| INSTR | 17.86 ± 9.23 | 13.02 ± 6.10** | 12.12 ± 5.48** | 1.5/0.239 (0.081) | 0.1/0.744 (0.006) |
| Control | 18.84 ± 10.89 | 15.66 ± 7.77 | 13.10 ± 5.68* | ||
| Fast walking speed (m/s)† | |||||
| INSTR | 0.89 ± 0.28 | 1.10 ± 0.38* | 1.22 ± 0.34** | 1.0/0.341 (0.054) | 1.9/0.188 (0.100) |
| Control | 0.90 ± 0.30 | 1.04 ± 0.34 | 1.10 ± 0.43 | ||
| Barthel Index† | |||||
| INSTR | 82.5 ± 10.6 | – | 92.5 ± 10.6* | – | 1.4/0.248 (0.078) |
| Control | 78.0 ± 14.2 | – | 85.5 ± 12.6* | ||
Abbreviations: ANCOVA, analysis of covariance; MDS-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; TUG, timed up and go.
†Significance levels of *p < 0.05 and **p < 0.01 in intragroup comparisons (T0 vs. T1 or T0 vs. T2) using the Wilcoxon signed-rank test.
‡Significance levels of *p < 0.05, **p < 0.01, ***p < 0.001 in ANCOVA.
Fig. 2(A) MDS-UPDRS part III score: mean change from T0. (B) Pull test score (blinded rating): mean change from T0. Compared with that in the control group (interrupted line), the change between T0 and T2 was superior in the INSTR group (solid line); *p < 0.05, **p < 0.01 in ANCOVA. MDS-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; ANCOVA, analysis of covariance.